Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Study:

A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease

Rationale:

n/a

Purpose:

This study is being conducted to learn about the safety and risks of using OncoVEXGM-CSF to treat patients with melanoma and to see if OncoVEXGM CSF can destroy these tumours compared to GM-CSF. This study may provide information on the usefulness of OncoVEXGM-CSF as a future treatment for melanoma. This study may also provide information on the safety and usefulness of GM-CSF as compared to OncoVEXGM-CSF as a treatment for melanoma.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Melanoma Biological: OncoVEXGM-CSF (talimogene laherparepvec)
Biological: GM-CSF
Phase 3

Verified by BioVex Limited June, 2012

Sponsored by: BioVex Limited
Information provided by: BioVex Limited
ClinicalTrials.gov identifier: NCT00769704

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio 44195
United States

MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site